Status:
COMPLETED
Effectiveness of A Hemodynamic-Guided Treatment Strategy to Improve Blood Pressure Control
Lead Sponsor:
Peking University People's Hospital
Collaborating Sponsors:
Yale University
Shanghai Jiao Tong University School of Medicine
Conditions:
Hypertension
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
A single-center, single-blind, randomized study to investigate the effectiveness of a hemodynamic-guided treatment strategy to improve blood pressure control
Detailed Description
Hypertension is a hemodynamic-related disorder characterized by abnormalities of the cardiac output (CO) and/or systemic vascular resistance (SVR). It is hypothesized that selecting antihypertensive t...
Eligibility Criteria
Inclusion
- office BP \>= 140/90 mmHg
- hypertensive patients who were treatment naive or previously treated with 1-3 anti-hypertensives
- age 18-85, males or females
- agree to sign informed consent
Exclusion
- having unstable hemodynamics diseases, or had myocardial infarction (MI), heart failure (HF) or chronic kidney disease (CKD) within previous 6 months
- using large doses of diuretics or beta-blockers (usually refers to double max doses) and can not stop dosing
- atrial fibrillation (AF) or severe arrhythmia
- severe aortic regurgitation
- severe thoracic fluids
- height weight out of ranges: 120-230 cm30-230 kg
- using more than 3 antihypertensives
- known secondary hypertension
- refused to sign informed consent
Key Trial Info
Start Date :
December 31 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT04715698
Start Date
December 31 2018
End Date
December 31 2019
Last Update
January 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, China